Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL - PubMed
4 hours ago
- #Acalabrutinib
- #CLL/SLL
- #Ibrutinib
- Bruton tyrosine kinase inhibitors (BTKis) are standard therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
- The study compared second-generation BTKi acalabrutinib with first-generation ibrutinib in treatment-naive CLL/SLL patients.
- Acalabrutinib had fewer discontinuations due to intolerability (19.4% vs 46.7%; p<.001) than ibrutinib.
- Acalabrutinib showed a lower risk of new/worsening hypertension (HR 0.27; 95% CI, 0.14-0.55; p<.001) compared to ibrutinib.
- Acalabrutinib prolonged time to treatment failure (TTF) (HR 0.42; 95% CI, 0.31-0.56; p<.001) versus ibrutinib.
- The study supports acalabrutinib's more favorable cardiovascular toxicity profile and efficacy over ibrutinib.